Versant Diagnostics Expands Collaboration with Leica Biosystems as PRW Laboratories Becomes First to Deploy Aperio GT Elite Solution

Versant Diagnostics and Leica Biosystems: Milestone deployment reflects growing demand for high-throughput, AI-enabled digital pathology workflows

VISTA, CA, June 24, 2026 – Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician services company actively engaged in next-generation digital pathology, announce an expanded collaboration to advance digital pathology adoption. PRW Laboratories, in partnership with Versant Diagnostics and Versant DermPath, has become the world’s first laboratory to deploy the recently-launched Aperio GT Elite solution.

Designed for high-throughput, time-critical digital pathology workflows, the Aperio GT Elite scanner helps accelerate slide processing and review with minimal manual intervention and rework. It can scan as fast as 22 seconds per slide and integrate LIS data to drive automated scanning protocols based on criteria such as tissue or stain type.

“Innovation in digital pathology needs to do more than introduce something new; it needs to help laboratories move forward with confidence,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “At Leica Biosystems, we’ve built our leadership in this space by combining deep pathology expertise with a long-term commitment to advancing what’s possible across the workflow. The introduction of the Aperio GT Elite solution reflects that ongoing focus and our responsibility to help shape the future of digital and computational pathology in a way that is practical, scalable, and grounded in the real needs of laboratories.”

The deployment reflects growing adoption of high-throughput, AI-enabled digital pathology workflows and builds on a longstanding collaboration between Leica Biosystems and Versant Diagnostics. Before adding the Aperio GT Elite solution, Versant Diagnostics leveraged the Leica Biosystems Aperio GT 450 scanner to digitize whole slide images, alongside Indica Labs’ HALO AP® as their image management solution.

“When we started our digital journey, we weren’t simply looking for an equipment vendor—we were looking for a true partner who shared our vision for the future of patient care,” said Lola Leibensperger, Versant Diagnostics’ Chief Operating Officer. “Becoming the first laboratory network in the world to implement Leica Biosystems’ Aperio GT Elite scanners at Versant Diagnostics and PRW Laboratories is a testament to that shared commitment. This milestone isn’t just about adopting cutting-edge technology; it’s about pioneering digital innovation together to enhance accuracy, streamline laboratory workflows, and ultimately deliver faster, more precise diagnostics for the patients who depend on us.”

“As digital pathology hardware and software continue to evolve rapidly, selecting a vendor is about more than choosing the best solutions available today—it is also about partnering with an organization that can provide ongoing access to innovation and support,” said Clay Hillyer, Senior National Sales Director at Leica Biosystems. “As a global leader in digital pathology, Leica Biosystems is committed to delivering both advanced products and a robust innovation pipeline that helps customers deploy and scale digital pathology to its fullest potential. We are proud to continue that commitment to Versant Diagnostics and PRW Laboratories through this deployment of the Aperio GT Elite solution.”

The Aperio GT Elite solution is one of the most recent innovations within Leica Biosystems’ comprehensive digital and computational pathology ecosystem and expands the company’s portfolio of end-to-end solutions–the only provider in the industry to span the full anatomic pathology workflow. Leica Biosystems is trusted by 100% of the Top 50 Hospitals for Cancer, as well as the National Cancer Institute‑Designated Cancer Centers, and holds the largest digital pathology instrument install base worldwide.

With planned expansion and broader availability of the Aperio GT Elite solution across additional global markets, Leica Biosystems continues to enable access to high-performance digital pathology solutions worldwide.

For Research Use Only. Not for Use in Diagnostic Procedures.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. Learn more at www.leicabiosystems.com.

About Versant Diagnostics

Founded in 2021 by physician Ven Aduana, M.D. and operating executives Jim Billington and Brian Carr, Versant Diagnostics is focused on anatomic pathology and the digital transformation of the industry. By combining technological advancements in healthcare with a skilled set of subspecialty pathologists, Versant Diagnostics aims to provide superior service for hospitals and physician practices. Learn more at www.versantdx.com.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Media Contact: Matthew McCutcheon, Global External Communications Senior Manager, matthew.mccutcheon@leicabiosystems.com

SOURCE: Leica Biosystems